Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Novavax is in a strong position to capitalize on the growing demand for vaccines with its promising technology and broad pipeline of potential products. Their recent partnerships with top global pharmaceutical companies and expansion into diverse fields such as oncology and infectious diseases only add to their potential for success. Additionally, the positive support from physician groups for the COVID vaccine and the potential for increased uptake of Nuvaxovid due to its better tolerability than mRNA vaccines bodes well for the company's commercial outlook. The risks to the downside for Novavax include failure to develop a successful combo vaccine and potential negative regulatory developments, but overall, the company's strong fundamentals and growing market opportunity make it a favorable investment opportunity.

Bears say

Novavax is a well-established biotechnology company with a promising pipeline of vaccine candidates, however, the recent tolerability data from Sanofi may not be enough to differentiate their product in a crowded COVID-19 vaccine market. The company's reliance on Matrix-M adjuvant and partnerships for value creation may also present potential risks and uncertainties. The declining market share predictions for Nuvaxovid and potential competition in the future may also negatively impact the company's financials and stock performance.

Novavax (NVAX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 6 analysts, Novavax (NVAX) has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.